Quantcast

Latest Uveal melanoma Stories

2014-09-29 08:30:43

- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept. 29, 2014 /PRNewswire/ -- Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented today at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. (NASDAQ: ARRY) and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2....

2014-09-04 16:28:00

Statement from Tim Turnham, Executive Director, Melanoma Research Foundation WASHINGTON, Sept. 4, 2014 /PRNewswire-USNewswire/ -- Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown. In clinical trials, 24 percent of patients taking pembrolizumab had their tumors shrink. Most of these patients...

2014-07-29 00:21:19

WASHINGTON, July 29, 2014 /PRNewswire-USNewswire/ -- Despite the epidemic rise in melanoma incidence and the increasingly heavy toll it is taking on young adults, this cancer has remained low on the public health radar screen. The report issued today by "the nation's doctor" changes the national conversation and recognizes that skin cancer is a major health threat that warrants coordinated action. Melanoma is the deadliest of all skin cancers and, on behalf of those fighting this disease,...

2014-07-17 12:30:59

Leading Nonprofits in Melanoma Applaud Allocation of New Funds, Pledge to Advance Breakthrough Melanoma Treatments WASHINGTON, July 17, 2014 /PRNewswire-USNewswire/ -- Today the Senate Appropriations Committee approved their fiscal year 2015 Defense Appropriations bill which includes $50 million for the Department of Defense's (DoD) Peer Reviewed Cancer Research Program (PRCRP), doubling the level of funding from fiscal year 2014. This announcement illustrates the Committee's...

2014-06-19 09:36:43

The JAMA Network Journals In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. Uveal melanoma arises from melanocytes within the choroid layer of the eye. There...

2014-06-02 12:29:47

Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and selumetinib, were showcased at the 50th annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and CDK4/6 inhibitor LEE011 (discovered by Novartis Institutes for BioMedical Research in collaboration with Astex...

2014-05-23 23:10:07

Melanoma Research Foundation presents Humanitarian Award. San Francisco, CA (PRWEB) May 23, 2014 Mohammed Kashani-Sabet, M.D., a physician with Sutter Pacific Medical Foundation and medical director for the Center for Melanoma Research and Treatment at California Pacific Medical Center (CPMC), will be honored with the sixth annual Humanitarian Award from the Washington, D.C.-based Melanoma Research Foundation on May 28. The Humanitarian Award is presented to those in the local community...

2014-05-14 08:30:37

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 - June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant...

2014-05-01 08:29:22

WASHINGTON, May 1, 2014 /PRNewswire-USNewswire/ -- The best way to fight one of the deadliest and fastest growing cancers may be to get naked. The Melanoma Research Foundation (MRF) announced today the launch of #GetNaked, a provocative new awareness campaign designed to prompt people to watch for potentially dangerous changes in moles on the skin. Research has shown that patients, not doctors, are most likely to spot their melanomas, so the MRF is encouraging people to #GetNaked...

2014-02-04 12:27:40

Program goal is improved understanding of individual risk for recurrence in patients diagnosed with early stage melanoma FRIENDSWOOD, Texas, Feb. 4, 2014 /PRNewswire/ -- Castle Biosciences Inc., a leading developer of diagnostic and prognostic tests for rare cancers, today announced the launch of an educational program dedicated to the information needs of Stage I and II skin (cutaneous) melanoma patients and their caregivers. The program kicks off with the launch of an animated...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.